Following Nvidia’s decision to walk away from its planned US$40bn takeover of Cambridge-based chip designer Arm from Japan’s Softbank, after regulatory hurdles proved insurmountable, speculation is growing over a potential return to the London Markets.
GCP Co-Living REIT plc, intends to float on the Main Market. The Company is a newly established, externally managed investment company, which it is intended will carry on business as a Real Estate Investment Trust, subject to meeting the necessary qualifying conditions. The Company will invest, predominantly, in independent Co-Living Asset, both operational and under development, let to a diversified mix of residents, located in urban centres in the UK and Ireland where there is a shortage of high quality, affordable residential accommodation. Due March.
Strip Tinning Holdings, an established supplier of specialist connectors to the automotive sector, intends to join AIM. Strip Tinning manufactures specialist flexible electrical connectors related primarily to heating and antennae systems embedded within automotive glazing and to the connection of the cells within electric vehicle (EV) battery packs, increasingly using flexible and lightweight printed circuit technology that also has growing application elsewhere within vehicles. Mkt Cap £28m.Due 16th Feb.
Spinnaker Acquisitions plc, intends to join the Main Market (Standard). The Company have conditionally agreed to acquire the entire issued share capital of HomeServe Labs Ltd, a wholly owned subsidiary of FTSE250 quoted public company HomeServe Plc, by way of a reverse takeover conditional, inter alia on relisting and successful completion of fundraising activities to be undertaken by way of a placing and direct subscriptions by new and existing investor. If the Proposed Transaction proceeds to completion, it is proposed to change the name of the Company to Ondo InsurTech Plc and the name of Labs, which will become a subsidiary of the Company, to LeakBot Ltd. Should the Proposed Transaction not proceed, then the Company would need to apply for the suspension of its listing of ordinary shares to be lifted and for trading to be restored. £5m capital to be raised. Due early 2022.
Clean Power Hydrogen, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser is seeking to join AIM. The Group designs and manufactures hydrogen production units and is focused on the commercial production of green hydrogen in a simple, safe, and sustainable manner. The Group intends to raise approximately £50m. Due Early Feb.
Carbon Air, a nano-technology company which leverages the adsorption properties of activated carbon and other advanced materials to improve suspension systems, enhance acoustics or reduce noise, to join AIM. The Company’s proprietary technology has allowed it to develop a unique portfolio of solutions for a variety of sizeable end markets, including vehicle suspension systems, acoustic insulation for domestic appliances and micro-speakers for smartphones. Mkt Cap and Capital to be raised TBC. Due Late Feb.
Spiritus Mundi due to join the Main Market (Standard), a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector. The Company has already raised approximately £1.2m in a pre-IPO fundraising round. Delayed until second half of Q1 2022.
Recycling Tech Group to join AIM, a UK-based engineering, research and manufacturing company that has developed a modular and mass producible machine, the RT7000, which processes hard to recycle plastic waste into a synthetic oil that can be sold back to the petrochemicals industry as a chemical feedstock to make new plastics. Targeting a £40m raise. Due early Q1 2022.
Nu-Oil and Gas to acquire Guardian Maritime Ltd and Guardian Barriers IP Ltd and become Guardian Global Security plc and join the Main Market (Standard). Guardian is a technology group that supplies products to prevent unauthorised entry into areas that are deemed to have value, with maritime security being the main focus initially. Due early Feb.
Superdielectrics to join AIM, a Company which is focused on developing technology to build supercapacitors with high energy density, low cost, and environmentally benign electrical energy storage devices that will help create a clean and sustainable global energy and transportation system. Admission is expected to take place in. Delayed until Mid-Feb. Mkt Cap and Capital to be raised TBC.
Ceres Power Holding 642p £1,224m (CWR.L)
Ceres Power Holdings plc, a global leader in fuel cell and electrochemical technology, announces that non-binding Heads of Terms have been signed setting out plans for a three-way collaboration with Weichai Power and Robert Bosch GmbH to access the substantial opportunities that exist for fuel cell technologies in China. The addition of Bosch to the existing Weichai and Ceres partnership, and an increase in scope to include stationary power applications, significantly strengthens the planned joint venture. It is now intended that two separate Joint Ventures (“JVs”) will be formed in Shandong Province, specifically: three-way system JV will be set up for the development and manufacture of solid oxide fuel cell (SOFC) systems. Bosch and Ceres will licence their respective SOFC system IP to the JV for mobile and stationary applications in China and will share royalties from the sale of products. Weichai will be the majority shareholder. Ceres will hold a maximum 10% share with Board representation. Its investment over time is likely to be around £20m, to be finalised in the detailed agreements. Separately, a stack manufacturing JV (“Stack JV”) will be established to supply fuel cell stacks to the system JV and potentially other third parties. Ceres will not be a shareholder in this JV but will provide the SOFC technology through an extension of Bosch’s existing manufacturing licence to supply the Chinese market. Ceres will receive royalties from this JV on the sale of stacks. License fees of £30m from the System JV and Stack JV to Ceres are expected over the next three years in line with those agreed in the original Weichai-Ceres agreement in 2018, with minimum payments and annual royalties receivable following start of production from each of the JVs.
Chaarat Gold Holdings 18.13p £125m (CGH.L)
The AIM-quoted gold mining Company with an operating mine in Armenia, and assets at various stages of development in the Kyrgyz Republic, announces its production and operational results for the full year ended 31 December 2021. The Company has exceeded its 2021 production guidance at its Kapan Mine in Armenia, however the development of the Tulkubash project was impacted by the events around Centerra Gold’s Kumtor mine and ongoing COVID-19 pandemic in the Kyrgyz Republic. Highlights include: Kapan Mine: Finished the year with production of 63 thousand gold equivalent ounces (koz) including 14 koz from third-party ore production vs 2021 guidance of 57 koz (+10.5%); EBITDA contribution of approximately USD 22.7m at Kapan level in 2021 before group accounting adjustments and non-cash items (2020: USD 19m). Tulkubash Development Project: Successfully completed a 4,835-metre drilling programme including infill drilling and initial exploration drilling on new target areas. JORC-compliant resource and reserve estimates are being updated to reflect the infill drill results. Kyzyltash Development Project: Successfully completed a 3,508-metre drilling programme to obtain representative core of the Kyzyltash deposit ready for metallurgical testing. The core is being sent to SGS Lakefield in Canada for a full suite of metallurgical test work as part of assessing the preferred processing route for the project. Corporate Activities: Funding package of USD52.2m closed in February 2021. Reduced interest-bearing debt from USD70.5m as at 31 December 2020 to USD38.7m as at 31 December 2021 (-45.1%), primarily as result of converting investor and Labro loans into equity in February 2021 and reducing the Kapan acquisition loan by USD9m from Kapan cash flows.
Clinigen 918.25p £1,224m (CLN.L)
The global pharmaceutical Services and Products company, announces it has signed a distribution agreement, with Deciphera Pharmaceuticals for the supply and distribution of QINLOCK® into multiple countries across the globe. QINLOCK® was approved by the European Medicines Agency in November 2021 for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. Under the agreement, Clinigen will supply QINLOCK® into multiple countries where it is not yet commercially available. Clinigen will act as the main point of contact for healthcare professionals wanting to access QINLOCK®, managing all elements of the process including order and enquiry management, regulatory compliance, and logistics.
Distribution Finance 48p £86.1m (DFCH.L)
The specialist bank providing working capital solutions to dealers and manufacturers across the UK, announces that after a thorough search process including external candidates the Board has concluded to appoint Mark Stephens as Non-Executive Chair of the Company with immediate effect. Prior to this appointment, Mark was an existing Non-Executive Director of the Company, holding the position of Senior Independent Director since joining the Board on 3 July 2017 and has held the position of Interim Non-Executive Chair since May 2021. Following his appointment, Mark will continue to Chair the Company’s Remuneration and Nomination Committees. The Board has already started a search process of an Independent Non-Executive Director who will, once appointed, Chair the Risk Committee. In the intervening period, Carole Machell will additionally Chair the Company’s Risk Committee. These changes are subject to regulatory approval.
Iomart Group 162.5p £178.6m (IOM.L)
The cloud computing and managed services company, announces the appointment of Ben Savage as Chief Commercial Officer. Ben boasts more than 25 years’ experience working across a range of technology-based sales leadership roles. Ben has also worked for organisations head-quartered in Silicon Valley, Europe, and the Middle East. His most recent position as Managing Director, Sales and Marketing at managed service provider Six Degrees. Bringing with him a wealth of experience working with companies ranging from start-ups to large enterprises, Ben will oversee iomart’s sales team and overarching commercial strategy as well as being a central figure supporting the organisation’s growth ambitions.
Itaconix 3.4p £15.1m (ITX.L)
Itaconix, a leading innovator in plant-based specialty polymers used as essential ingredients in everyday consumer products, announces that it has supplied product for the first production trial using the Company’s plant-based superabsorbent, VELAFRESH® SAP80. VELAFRESH® SAP80 is being trialed by a leading supplier to companies that produce baby diapers, feminine hygiene products, adult diapers, and industrial absorption products. This follows the Company’s production trials for VELAFRESH® SAP80 in 2021. If the prospective customer’s trials are favourable, potential Itaconix revenues are expected to start in 2023. Increasing consumer interest in more sustainable hygiene products is generating new addressable markets for Itaconix’s plant-based polymers. The worldwide market for superabsorbent polymers was estimated at $9.0 bn in 2020 and is supplied almost entirely by fossil-based polymers due to the higher cost or lower performance of current plant-based polymers. The Company believes VELAFRESH® SAP80 offers a superior level of performance, cost, and availability for brands and consumers that are seeking more sustainable hygiene products.
Lexington Gold 3.75p £9.8m (LEX.L)
The gold exploration and development company with projects in North and South Carolina, USA, announces assay results received in respect of the first 11 drill holes from the Company’s Reverse Circulation (RC) drilling programme at its Carolina Belle Project. Results for the remaining 21 drillholes will be announced in due course once received from the SGS laboratory in Vancouver. Highlights include: Initial assay results for 11 of the 32 RC drill holes from the Company’s maiden drill campaign at Carolina Belle intersected the first gold mineralisation identified from drilling; Drilling has identified and confirmed the down-dip extension of the main historical ore-zone mined during the historical third party Iola and Uwarra gold mining operations with a confirmed down-dip extension intersection of 4m @ 2.1 g/t Au from 64m to 68m in hole CRBC-24; Significant gold mineralisation intersected in the Footwall and Hangingwall of the main ore-zone of the historical Iola and Uwarra gold mining operations with: 11m @ 1.01 g/t Au from 68m to 79m (combined Hangingwall, Footwall and mined out historical main ore-zone) in hole CRBC-22 including, Footwall intersection of 4m @ 1.62 g/t Au from 72m to 76m, Hangingwall intersection of 4m @ 0.7 g/t from 68m to 72m and main historical ore-zone intersected between 72.2m and 73.2m.
Oriole Resources 0.36p £7.1m (ORR.L)
The AIM-quoted exploration company focussed on West Africa, provided an exploration update for its 90%-owned Wapouzé gold project in Cameroon. During Q4-2021, the team completed a programme of soil sampling over the southwest extent of the Wapouzé licence, as well as trenching over previously-identified soil anomalies at the Bataol Zone in the east. Results reported today include a best trenching interval of 2.00 metres (‘m’) grading 4.06 grammes per tonne (‘g/t’) gold (‘Au’). Highlights include: Five trenches completed for a total of 2,524m at the Bataol Zone. All trenches have returned anomalous gold (using a 0.10 g/t Au cut-off) with best results including; 2.00m grading 0.53 g/t Au (WPT006), 2.00m grading 4.06 g/t Au (WPT007) and 1.50m grading 0.53 g/t Au and 2.00m grading 0.50 g/t Au (WPT008). Mineralisation is predominantly hosted by quartz veinlets within sedimentary schist; Soil sampling completed over the southwest of the Project area has returned grades of up to 141 ppb Au.
System1 Group 390p £50.2m (SYS1.L)
System1, the marketing decision-making platform, intends to issue quarterly updates for Q1 and Q3 of each year based on unaudited numbers. These updates are intended to keep investors informed of the Company’s performance between the interim and final trading updates and results announcements. System1 today issues the following update on trading for the quarter ended December 2021 (Q3). Revenue in Q3 rose 8% on the comparable period last year to £6.5m, and Data products represented 43% of the quarter’s revenue. Year-to-date revenue to the end of Q3 was 17% higher than the prior year at £18.9m, and Data revenue represented 39% of the year-to-date total (H1: 36%). Period-end cash, net of borrowings, was £8.1m, compared with £6.5m at end-March 2021. Profitability was in line with management’s expectations and reflected an increase in expenditure on people and platform as highlighted in the interim results announcement.
WANdisco 310.5p £186.1m (WAND.L)
The LiveData company, today announces it has completed a significant data migration for a major client to Microsoft’s Azure cloud. The migration demonstrates WANdisco’s continued momentum with LiveData Migrator, which is also embedded within Microsoft’s Azure ecosystem. The migration was transacted through Microsoft on a consumption basis. The Client owns and operates Canada’s largest railway, both in terms of revenue and the physical scale of its rail network. Using the LiveData Migrator platform, the Client successfully migrated data off its operational Hadoop cluster, to the Azure cloud. The Client plans to engage WANdisco to mutually evaluate future use cases for LiveData Migrator, including in IoT data. The scope of the current opportunity is for the migration of 70 TB of data. However, there is the potential for a significant amount of additional revenue with the potential to move another 30 PB of data to the cloud per year through LiveData Migrator.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
